Title	Credits	Expiration Date
Cancer Summaries and Commentaries Vol. 1, No. 1 Bevacizumab/Docetaxel in Advanced Breast Cancer Lapatinib With or Without Pazopanib in HER2-Positive MBC Trastuzumab/Pertuzumab for MBC That Had Progressed on Prior Trastuzumab Tanespimycin/Trastuzumab in HER2-Positive MBC That Had Progressed on Prior Trastuzumab Anastrozole/Gefitinib in Postmenopausal Women With Hormone Receptor–Positive MBC Cetuximab With or Without Carboplatin for Triple-Negative MBC	1	Aug 20, 2009
Case Studies in Breast Cancer Vol. 6, No. 2 First-line Treatment of HER2^– MBC	1	Aug 20, 2009
Case Studies in Colorectal Cancer Vol. 4, No. 1 Extended Biologic Treatment of a Patient With Metastatic Colorectal Cancer	1	Jul 15, 2009
The Evolving Paradigm of Molecular-Based Diagnosis and Targeted Therapies in Breast Cancer How Do We Counsel Our Breast Cancer Patients? Diagnostic Testing for Targeted Therapeutics: Lessons Learned From HER2 HER2-Targeted Therapy in the Adjuvant Treatment of Breast Cancer Neoadjuvant Trastuzumab in HER2-Positive Breast Cancer	1	Jun 30, 2009
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 1 Chemoimmunotherapy Regimens in Chronic Lymphocytic Leukemia: Recent Updates When and How to Treat Patients With Chronic Lymphocytic Leukemia	1	Jun 27, 2009
Case Studies in Pain Management Vol. 2, No. 1 Treatment of a Patient With Intractable Pain Due to Progressive Pancreatic Cancer	1	Jun 26, 2009
Case Studies in Ovarian Cancer Vol. 3, No. 1 Clinical Management of a Patient With Platinum-Resistant Ovarian Cancer	1	Jun 6, 2009
Oncology Consultations Vol. 5, No. 1 Therapeutic Options for ER⁺/HER2^- Breast Cancer	1	Jun 6, 2009
Patient Communication: The Surgeon's Role Interpretation of Breast Cancer Biomarkers Reviewing Individualized Benefits and Side Effects of Systemic Therapy: Decision Tools Communicating the Promises and Limitations of Targeted Therapy The Impact of Advocacy in Cancer Care and Research Learning How to Counsel Our Patients	1	Jun 6, 2009
Molecular Profiling:Improving Precision in Adjuvant Therapy Decisions for Early-Stage Breast Cancer Multigene Assays: A Window Into Breast Cancer Behavior	1	Jun 4, 2009
From Genome to Clinic: Translating Discoveries Into Practice Targeting Growth Factor Receptors: Current Impact and Future Potential Therapeutic Applications of Angiogenesis-Based Therapies	1	Jun 4, 2009
Rapid Reviews in Oncology: Update in Hematologic Malignancies Frontline Therapies for Multiple Myeloma: A New Landscape Evolving Strategies in the Management of Patients With Chronic Lymphocytic Leukemia Clinical Advances for Patients With Myelodysplastic Syndromes	1	Jun 3, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 3 Optimizing Treatment with Bcr–Abl Tyrosine Kinase Inhibitors in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia: Focus on Dosing Schedules	1.5	May 28, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 2 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma	1	May 27, 2009
Clinical Colorectal Cancer Vol. 7, Suppl. 1 New Developments in Targeted Treatment Strategies for Colorectal Cancer	1.25	May 27, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 1 Novel Agents for Hematologic Malignancies: An Era of Riches	1.25	May 27, 2009
Clinical Challenges in Non-Hodgkin Lymphoma: Biologic Strategies for 2008 Improving Outcomes in DLBCL by Altering Current Regimens Biologic Therapy in CLL: Current Data and Ongoing Studies Novel Anti-CD20 Antibodies in NHL Current Trends in Antiangiogenic Therapy in NHL Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma	1	May 15, 2009
Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer The Success of Targeting the Vascular Endothelial Growth Factor Receptor Axis in Renal Cell Carcinoma Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent Renal Cell Carcinoma Risk Prognostication and Tumorigenesis in Prostate Cancer Current Approaches to Prevention and Early Intervention in Prostate Cancer	1	May 14, 2009
Breast Cancer Journal Club Vol. 5, No. 2 Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer	1	May 6, 2009
Case Studies in Breast Cancer Vol. 6, No. 1 ErbB TKIs in ErbB2-Positive IBC	1	May 5, 2009
Case Studies in Lymphoma Vol. 6, No. 2 A Patient With Peripheral T-Cell Lymphoma Treated With a Histone Deacetylase Inhibitor	1	May 5, 2009
Controversies in Adjuvant Endocrine Therapy for Breast Cancer Adjuvant Endocrine Therapy in 2007: What Have We Accomplished and What Uncertainties Remain? Optimizing Endocrine Therapy for Patients With Newly Diagnosed Early-Stage Breast Cancer Controversies in Adjuvant Endocrine Therapy: Extending Therapy Beyond 5 Years Should All Patients Receiving Adjuvant Aromatase Inhibitors for Breast Cancer Receive Bisphosphonate Support?	1	Apr 25, 2009
Practical Updates in Breast Cancer Adjuvant Chemotherapy for Early-Stage Breast Cancer	2	Apr 15, 2009
Clinical Challenges With Hereditary and Transfusion-Dependent Iron Overload Hereditary Hemochromatosis and Iron Overload Disorders Mechanisms of Action of Iron Chelating Agents Current Perspectives in Measuring LIC Managing Iron Overload in Transfusion-Dependent Patients	1	Apr 4, 2009
Case Studies in Lymphoma Vol. 6, No. 1 Romidepsin in MF and Histologic Large-Cell Transformation	1	Mar 17, 2009
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer The Dilemma of Single Versus Combination Therapy: Which Agents and What Clinical Situation? Combinations of Chemotherapy and Biologically Targeted Agents: The Nature of the Synergy and Side-Effect Profile Locally Advanced Breast Cancer as a Model for the Study and Optimization of Chemotherapeutic Regimens The Use of Protein and Genetic Markers in Determining Optimal Chemotherapy: Ready for Prime Time? A Case-Based Debate	1	Mar 10, 2009
Oncology Briefings Vol. 6, No. 2 Update on Targeted Therapies in Chronic Myeloid Leukemia	0.5	Mar 3, 2009
Practical Updates in Renal Cell Carcinoma Utilizing Prognosis Assessment for Treatment Strategy Development in Metastatic Renal Cell Carcinoma Case 1: A 65-year-old male Case 2: A 48-year-old female Case 3: A 64-year-old female	1	Mar 3, 2009
Clinical Breast Cancer Vol. 8, Suppl. 1 Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors New Strategies for the Treatment of Metastatic Bone Disease	1.5	Mar 3, 2009
Oncology Briefings Vol. 6, No.1 Update on Histone Deacetylase Inhibitors in the Treatment of T-Cell Lymphoma and Multiple Myeloma	0.5	Mar 3, 2009
Clinical Advances in Breast Cancer Vol. 1, No. 1 HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management Role of Genomics and Emerging Novel Molecular Diagnostic Tests in the Routine Management of Early-Stage Breast Cancer	1	Mar 3, 2009
Targeted Therapies in Oncology The Extrinsic Pathway: Targeting Death Receptors in Cancer Therapy Targeting the Cell Cycle and DNA Repair Machinery for Cancer Therapy	1	Mar 3, 2009
Oncology Consultations Vol. 4, No. 12 Treatment of HER2-Positive/Hormone Receptor Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy	1	Mar 3, 2009
Oncology Briefings Vol. 5, No. 4 Current and Novel Treatment Strategies for Newly Diagnosed Multiple Myeloma	0.5	Feb 15, 2009
Clinical Colorectal Cancer Vol. 6, Suppl. 2 Current Practice and Progress with Targeted Therapies in Colorectal Cancer	1.5	Jan 31, 2009
Advances in Lung Cancer Vol. 7, No. 4 Newly Diagnosed, Advanced-Stage Non–Small-Cell Lung Cancer: Considerations for First-line Treatment Second- and Third-line Treatment Options for Advanced Non–Small-Cell Lung Cancer Agents Targeting Mammalian Target of Rapamycin and Heat Shock Protein 90 in Non-Small-Cell Lung Cancer	1	Jan 17, 2009
Angiogenesis in Oncology Vol. 2, No. 6 Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy Combined Modality Therapy in Early-Stage Non-Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents Targeting the Tumor Microenvironment	1	Jan 17, 2009
Oncology Consultations Vol. 4, No. 13 Multidisciplinary Management in Patients Presenting With Resectable or Borderline-Resectable Stage IV Colorectal Cancer	1	Jan 17, 2009
Case Studies in Breast Cancer Vol.5 No.10 Treatment of a Patient With Relapsed ErbB2-Positive Metastatic Breast Cancer With Lapatinib	1	Dec 26, 2008
Emerging Biologic Approaches for the Treatment of Breast Cancer Who Needs Adjuvant HER2-Targeted Therapy? Novel Therapies for HER2-Positive Breast Cancer Confusion on the HER2 Front: Not All Decisions Are Black and White Inhibiting the Tumor Microenvironment Targeting Oncogene Addiction in Breast Cancer: Key Pathways and Novel Targets	1	Dec 22, 2008
Oncology Consultations Vol. 4, No. 11 Combination Biologic Therapy and Chemotherapy for Metastatic CRC Dual Biologics in Advanced CRC: CALGB/SWOG 80405 Trial Final Results of the BOND-2 Trial Chemotherapy-Associated Liver Toxicity	1	Dec 22, 2008
Advances in Colon Cancer Vol. 8, No. 2 Preclinical and Early Clinical Data on TRAIL in Colon Cancer The Pathogenesis of Colon Cancer: Role of the Extrinsic (Death Receptor) Pathway of Apoptosis	1	Dec 22, 2008
Oncology Consultations Vol. 4, No. 10 Q&A: Impact of Patient and Tumor Characteristics in Lung Adenocarcinoma SB 1: Second-Line Therapy for Advanced NSCLC SB 2: Impact of Smoking History on Therapy With EGFR TKIs in Lung Cancer	1	Dec 22, 2008
Biological Therapy of Breast Cancer Vol. 8, No. 4 Rationale and Clinical Data for Combined Inhibition of HER2 and Vascular Endothelial Growth Factor Receptor Pathways in Breast Cancer Genomic Rearrangements in Breast Cancer: Clinical Implications Putative Breast Cancer Stem Cells as Therapeutic Targets	1	Dec 14, 2008
Controversies in Biologic Therapy of Breast Cancer Controversies in Adjuvant Therapy: Treatment Options for Patients With Node-Negative, HER2-Positive, Early-Stage Breast Cancer Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Positive Disease Controversies in Metastatic Breast Cancer: Treatment Options for HER2-Negative Disease	1	Dec 14, 2008
Monographs in Hepatocellular Carcinoma Vol. 1, No. 1 Current Perspectives: Etiology and Molecular Pathogenesis of Hepatocellular Carcinoma Targeted Therapy for Hepatocellular Carcinoma: Overview of Current and Future Trials Treatment Approaches for Localized Hepatocellular Carcinoma	1	Dec 14, 2008
Targeted Therapies in Oncology Vol. 6, No. 1 Novel Strategies for Treating Ovarian Cancer Emerging Monoclonal Antibodies for the Treatment of HER2-Positive Breast Cancer	1	Dec 7, 2008
Targeted Therapies and Evolving Treatment Paradigms for Lung Cancer Molecular Pathogenesis of NSCLC Individualizing Therapies in NSCLC Based on Tumor Biology and Patient Characteristics Optimizing the Use of EGFR Inhibitors in Patients With NSCLC Integration of Antiangiogenesis Agents Into Treatment Paradigms for NSCLC Quality of Life and Adverse Events Associated With targeted Therapy in NSCLC New Therapeutic Agents for NSCLC	1	Dec 7, 2008
Cancer Abstracts & Summaries Vol. 8, No. 8 Targeted Agents in NSCLC: Novel Agents, Novel Settings Phase III Trial of First-line Gemcitabine/Cisplatin/Bevacizucmab in Advanced Nonsquamos NSCLC Phase III Trial of Gefitinib Compared to Docetaxel in Patients With Previously Treated Advanced NSCLC Phase II Trial of First-line Erlotinib in Patients With Advanced or Metastatic NSCLC Phase II Trial of First-line XL647 in Patients With NSCLC Enriched for Sensitivity to EGFR Tyrosine Kinase Inhibitors Ongoing Phase II/III Trials of Antiangiogenic Agents in NSCLC	1	Dec 7, 2008
Rapid Reviews in Oncology: Practical Updates on the Management of Multiple Myeloma Introduction and Overview Expert Interviews: A Conversation on Practical Updates in the Management of Multiple Myeloma With Dr. Asher Chanan-Khan and Dr. Sagar Lonial Integration of Anthracyclines Into the Management of Patients With Relapsed/Refractory Multiple Myeloma Advances in Treatment Options for Patients With Newly Diagnosed Multiple Myeloma	1	Dec 7, 2008
Angiogenesis in Oncology Vol. 2, No. 5 Incorporating Antiangiogenic Agents Into the Perioperative Setting for Colorectal Cancer Biology and Management of Hypertension and Other Class-Effect Toxicities Related to Antiangiogenic Therapy Novel Avenues in Antivascular Tumor Therapy	1	Dec 6, 2008
Beyond Taxanes: New Chemotherapeutic Options for Patients With Refractory Metastatic Breast Cancer Multidrug Resistance and Microtubule-Inhibiting Agents: Underlying Mechanisms and Predictive Factors Epothilones and Other Novel Microtubule-Targeting Agents in Clinical Development Practical Management of Resistant/Refractory Metastatic Breast Cancer	1	Nov 30, 2008
Current Perspectives on Targeted Therapies for Advanced Renal Cell Carcinoma Neoadjuvant Targeted Therapy Approaches in Advanced RCC Targeted Therapies as Standard of Care in mRCC Are Multitargeted TKIs the Standard of Care in Patients With Previously Treated mRCC? Sequential Targeted Therapy in RCC	1	Nov 30, 2008
Optimal Application of Epidermal Growth Factor Receptor and Angiogenesis Inhibitors in Lung Cancer Targeting Angiogenesis in Non-Small-Cell Lung Cancer Novel High-Affinity Vascular Endothelial GrowthFactor/Multitargeted Tyrosine Kinase Inhibitors Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non—Small-Cell Lung Cancer: Where Are We in 2007? Overcoming Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors	1	Nov 30, 2008
Utilizing Genomic Tools for Decision Making in Hormone Receptor-Positive Early-Stage Breast Cancer Genomic Tools for Decision Making in Early-Stage Breast Cancer	1	Nov 30, 2008
Cancer Conference Highlights Vol. 9, No. 9 Current and Future Therapeutic Options for Patients With Advanced Hormone-Refractory Prostate Cancer Novel Oral Platinum Analogues in the Treatment of Patients With Hormone-Refractory Prostate Cancer Satraplatin in Hormone-Refractory Prostate Cancer Molecular-Targeted Agents in Advanced Prostate Cancer Targeting Epigenetics in Prostate Cancer	1	Nov 30, 2008
The Evolving Utility of Biologic Therapy in Breast Cancer Optimizing Adjuvant Therapy With HER2-Targeted MoAbs Clinical Utility and Future Prospects of Small-Molecule HER TKIs Breast Cancer Resistant to HER2-Targeted Therapies Clinical Utility and the Future of Angiogenesis Inhibitor Therapy Emerging Applications of IGF-1R–Targeted Therapy	1	Nov 20, 2008
Oncology Consultations Vol. 4, No. 9 Treatment of a Premenopausal Patient With HR-Positive/Node-Negative Breast Cancer With Adjuvant Therapy	1	Nov 20, 2008
Novel Cytotoxic and Targeted Agents in Lymphoproliferative Disorders Bifunctional Alkylators Plus Other Cytotoxic Agents in Lymphomas Incorporating Proteasome Inhibitors Into Treatment of MCL Novel Approaches to CLL: MoAbs Plus Novel Cytotoxic Agents The Role of Novel Antibodies in Hematologic Malignancies	1	Nov 20, 2008
Controversies in Management of Non-Hodgkin Lymphoma Debate 1: The 2007 Standard of Care for Aggressive Lymphomas Should Be R-CHOP Every Two Weeks Debate 2: All Patients With Follicular Lymphoma Should Receive Maintenance Rituximab Debate 3: Rituximab Plus Chemotherapy Followed by Autologous Stem Cell Transplantation Consolidation Is the Optimal Therapy for Mantle Cell Lymphoma	1	Nov 20, 2008
Oncology Briefings Vol.5, No.8 Novel Paclitaxel Formulations	0.5	Nov 20, 2008
New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes Individualization of HER2-Targeted Therapy in Early-Stage Breast Cancer Novel Approaches to HER2-Positive Breast Cancer: Emerging Targeting Agents Practical Considerations for Angiogenesis Inhibition in Advanced Breast Cancer Multiplying the Benefits: Novel Combinations of Targeted Agents Contributions of c-Myc Amplification and Other Genetic Alterations in HER2-Positive Breast Cancer	1	Nov 20, 2008
Advances in Lung Cancer Vol. 7, No. 3 Response to TKIs Targeting EGFR Second-Generation EGFR TKIs	1	Nov 20, 2008
Translating the Complexities of Cancer Development Into Novel Therapeutics Summaries of Lectures From a Satellite Symposium Held in Conjunction With the 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1-5, 2007	1	Nov 20, 2008
Emerging Pathways With Therapeutic Potential in Cancer Targeting Signaling Pathways to Inhibit Cancer Growth Targeting the MAP/MEK and PI3K/Akt Pathways Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer Vaccines in Lung Cancer Novel Immunologic Targets in Metastatic Melanoma Combining Targeted Agents to Improve Therapeutic Efficacy	1	Nov 20, 2008
Advances in Microtubule-Targeting Strategies in Breast Cancer History of Microtubule-Targeted Agents in Breast Cancer as a Model for Drug Development Novel Microtubule-Targeting Agents in Clinical Development in Breast Cancer	1	Nov 19, 2008
Clinical Breast Cancer Vol. 7, Suppl. 1 Evolving Strategies in the Maintenance of Bone Health in Breast Cancer	1.5	Oct 31, 2008
Oncology Consultations Vol. 4, No. 7 Chemotherapy Plus HER2-Targeted Therapy	1	Oct 31, 2008
Cancer Abstracts & Summaries Vol. 8, No. 7 Recent Advances in NHL Phase III Trial of R-HDS Compared to R-CHOP in High-Risk FL Maintenance Rituximab in Elderly Patients With DLBCL Phase II Study of Lenalidomide in Relapsed/Refractory NHL Phase II Study of Bortezomib/R-CHOP in Treatment-Naive BCL Low Doses of hA20 in Relapsed/Refractory NHL	1	Oct 31, 2008
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 12, No. 2 Emerging Strategies for Eradicating MRD in CLL Role of Alemtuzumab in Transplantation for CLL	1	Oct 31, 2008
Oncology Consultations Vol. 4, No. 8 Advances in the Treatment of Patients With Metastatic Hepatocellular Carcinoma	1	Oct 31, 2008
Advances in Pancreatic Cancer Vol. 1, No. 1 Changing Standards of Care in Resectable Pancreatic Cancer: Recent Data and Ongoing Trials Integrating Antiangiogenic Therapies Into the Treatment of Pancreatic Cancer Update on the Use of Epidermal Growth Factor Receptor-Targeted Therapies in Pancreatic Cancer	1	Oct 31, 2008
The Interface Between Molecular Biology and Clinical Practice: Targeting the Ras/Raf Signaling Network in Cancer Efficacy of Biologic Targeted Agents in Hepatocellular Carcinoma Antiangiogenic Agents in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer Beyond Proof of Principle for Multikinase Inhibitors in Renal Cell Carcinoma Clinical Update on Therapeutic Inhibition of Raf in Metastatic Melanoma	1	Oct 31, 2008
Oncology Briefings Vol. 5, No. 5 New Agents in the Treatment of Metastatic Melanoma	0.5	Oct 22, 2008
Oncology Briefings Vol. 5, No. 7 Advances in Chemotherapy for Metastatic NSCLC	0.5	Oct 22, 2008
Oncology Briefings Vol. 5, No. 6 Tyrosine Kinase Inhibitors as Adjuvant Therapy in Resectable Gastrointestinal Stromal Tumors	0.5	Oct 15, 2008
Oncology Consultations Vol. 4, No. 6 Treatment of a Patient With Metastatic Adenocarcinoma of the Lung	1	Oct 15, 2008
Optimizing Strategies for Targeting CD20 in B-Cell Lymphoproliferative Disorders CAAS Effector Mechanisms of Antitumor Antibodies	1	Oct 15, 2008
Tailoring ErbB-Directed Therapies for Optimized Care of Breast Cancer Patients Structural Basis of ErbB Signaling and ErbB-Targeted Therapies Adjuvant/Neoadjuvant Strategies for Targeting ErbB2-Positive Early-Stage Breast Cancer Targeted Therapy Options for ErbB2-Positive MBC Downstream Modulators of ErbB2 Activity Relationship Between ErbB and ER Signaling Pathways	1	Sep 30, 2008
Case Studies in Pain Management Vol. 1, No. 2 A Patient With Metastatic Breast Cancer to the Spine With Critical Stenosis and Pain Treated With Intrathecal Ziconotide	1	Sep 30, 2008
Targeting the Epigenome and Overcoming Kinase Mutations in Hematologic Malignancies Modulating Epigenetic Mechanisms in Hematologic Malignancies Epigenetic Therapy in Hematologic Malignancies HDACIs in Hematologic Malignancies Future Directions and Challenges for HDAC Inhibition Bcr-Abl TKIs in CML and Ph⁺ ALL MK-0457 in Imatinib-Resistant CML	1	Sep 30, 2008
Case Studies in Oncology Vol. 8, No. 6 A Patient With Metastatic Renal Cell Carcinoma Treated With Bevacizumab/Interferon Alfa	1	Sep 30, 2008
Case Studies in Oncology Vol. 8, No. 7 A Patient With Primary Localized Gastrointestinal Stromal Tumor Treated With Neoadjuvant Imatinib	1	Sep 30, 2008
Cancer Abstracts & Summaries Vol. 8, No. 6 Optimizing the Application of Targeted Agents in Non–Small-Cell Lung Cancer	1	Sep 30, 2008
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 12, No. 1 Alemtuzumab in Relapsed/Refractory CLL Genomic Profiling in CLL	1	Sep 15, 2008
Cancer Conference Highlights Vol. 9, No. 8 Adjuvant Trastuzumab Biomarkers Predictive of Response and Toxicity Associated With Trastuzumab Novel Developments in Small-Molecule HER2 Inhibitors Novel MoAb-Based Approaches in MBC Growth Factors and Their Inhibitor	1	Aug 31, 2008
Cancer Abstracts & Summaries Vol. 8, No. 5 Adjuvant Chemotherapy With or Without Trastuzumab in HER2-Positive Breast Cancer First-line Paclitaxel/Lapatinib in MBC Phase II Trial of First-line Capecitabine/Bevacizumab in MBC Phase II Trial of First-line Docetaxel With or Without Axitinib in MBC Phase II Trial of Pertuzumab/Trastuzumab in HER2-Positive MBC	1	Aug 31, 2008
Oncology Briefings Vol. 5, No. 3 First-line Chemotherapy/Targeted Agents in Advanced Pancreatic Cancer	1	Aug 31, 2008
Cancer Abstracts & Summaries Vol. 8, No. 4 New Targeted Agents and Combinations in RCC First-line Interferon Alfa-2a/Bevacizumab in mRCC Sunitinib/Bevacizumab in mRCC Temsirolimus or Interferon Alfa in Advanced RCC Temsirolimus/Bevacizumab in Advanced RCC Axitinib in Sorafenib-Refractory mRCC Pazopanib in Metastatic Clear Cell RCC mTOR Inhibition by Everolimus in RCC	1	Aug 31, 2008
Innovations in Breast Cancer: Novel Strategies for Targeting Microtubules Novel Microtubule-Targeting Agents in Metastatic Breast Cancer Epothilones and Other Novel Microtubule-Targeting Agents in Metastatic Breast Cancer	1	Aug 31, 2008
Biological Therapy of Breast Cancer Vol. 8, No. 3 Increasing the Therapeutic Index of Traditional Chemotherapeutics Role of the Tumor Stroma in Breast Cancer and Treatment Immune-Mediated Antitumor Effects With Antibody Therapy	1	Aug 31, 2008
Cancer Abstracts & Summaries Vol. 8, No. 3 Targeted Therapies in Hepatocellular and Renal Cell Carcinomas Phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol Trial of Sorafenib Compared to Placebo in Patients With Advanced Hepatocellular Carcinoma Efficacy and Safety of Sunitinib in Patients With Advanced Hepatocellular Carcinoma Initial Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America Survival and Biomarker Analysis From a Phase III Trial of Sorafenib in Advanced Renal Cell Carcinoma: Final Results of TARGET Phase III Trial of Sunitinib Compared to Interferon Alfa as First-line Therapy for Metastatic Renal Cell Carcinoma: Updated Efficacy and Prognostic Factor Report	1	Aug 31, 2008

Highlighted Publications

Oncology Briefings Vol. 5, No. 7

Expiration Date: Oct 22, 2008

Monographs in Hepatocellular Carcinoma Vol. 1, No. 1

Expiration Date: Dec 14, 2008

Publications

Browse Publications By...

Search All Publications

Highlighted Publications

What's New

Contact PER